Should I buy or sell iTeos Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for iTeos Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ITOS shares. View ITOS analyst ratings or view top-rated stocks .

What is iTeos Therapeutics' stock price target for 2024?

3 brokerages have issued twelve-month price objectives for iTeos Therapeutics' stock. Their ITOS share price targets range from $18.00 to $44.00. On average, they predict the company's stock price to reach $30.33 in the next twelve months. This suggests a possible upside of 200.9% from the stock's current price. View analysts price targets for ITOS or view top-rated stocks among Wall Street analysts .

How have ITOS shares performed in 2024?

iTeos Therapeutics' stock was trading at $10.95 at the start of the year. Since then, ITOS stock has decreased by 7.9% and is now trading at $10.08. View the best growth stocks for 2024 here .

When is iTeos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our ITOS earnings forecast .

How were iTeos Therapeutics' earnings last quarter?

iTeos Therapeutics, Inc. (NASDAQ:ITOS) posted its quarterly earnings data on Wednesday, March, 6th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($1.03) by $0.18.

What ETFs hold iTeos Therapeutics' stock?

ETFs with the largest weight of iTeos Therapeutics (NASDAQ:ITOS) stock in their portfolio include Loncar China Biopharma ETF (CHNA) and Range Cancer Therapeutics ETF (CNCR) . Virtus LifeSci Biotech Clinical Trials ETF (BBC) .

What other stocks do shareholders of iTeos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iTeos Therapeutics investors own include Advanced Micro Devices (AMD) , GW Pharmaceuticals (GWPH) , Trevena (TRVN) , Blink Charging (BLNK) , Chegg (CHGG) , Centene (CNC) , Datadog (DDOG) , Global Blood Therapeutics (GBT) and Genocea Biosciences (GNCA) .

When did iTeos Therapeutics IPO?

iTeos Therapeutics (ITOS) raised $151 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are iTeos Therapeutics' major shareholders?

iTeos Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.08%) and Allspring Global Investments Holdings LLC (0.03%). Insiders that own company stock include Aaron I Davis, Ansbert Gadicke , Bioventures 2014 LP Mpm, Bioventures 2018 LP Mpm, Boxer Capital, Llc, David Hallal , Detlev Biniszkiewicz , Joanne Jenkins Lager , Les B Korsh , Matthew Gall , Michel Detheux and Yvonne Mcgrath . View institutional ownership trends .

How do I buy shares of iTeos Therapeutics?

Shares of ITOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ITOS

iTeos Therapeutics (ITOS) Stock Price, News & Analysis

→ Will this $2 AI stock double overnight? (From Behind the Markets) (Ad)

Free ITOS Stock Alerts

$10.56

+0.23 (+2.23%)

(As of 04:21 PM ET)

Compare

Today's Range: $10.01
▼
$10.61
50-Day Range: $9.89
▼
$13.64
52-Week Range: $8.20
▼
$18.24

Volume: 939,685 shs
Average Volume: 277,508 shs
Market Capitalization: $378.47 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $30.33

Get iTeos Therapeutics alerts:

iTeos Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 200.9% Upside
$30.33 Price Target
Short Interest: Bearish
7.19% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($4.76) to ($6.19) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.22 out of 5 stars

Medical Sector

753rd out of 918 stocks

Biological Products, Except Diagnostic Industry

129th out of 151 stocks

3.5

Analyst's Opinion

Consensus Rating
iTeos Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
iTeos Therapeutics has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
7.19% of the float of iTeos Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
iTeos Therapeutics has a short interest ratio ("days to cover") of 7.2.
Change versus previous month
Short interest in iTeos Therapeutics has recently increased by 1.99%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
iTeos Therapeutics does not currently pay a dividend.
Dividend Growth
iTeos Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ITOS.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for iTeos Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 12 people have searched for ITOS on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
MarketBeat Follows
8 people have added iTeos Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, iTeos Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
10.20% of the stock of iTeos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
97.16% of the stock of iTeos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for iTeos Therapeutics are expected to decrease in the coming year, from ($4.76) to ($6.19) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of iTeos Therapeutics is -3.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of iTeos Therapeutics is -3.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
iTeos Therapeutics has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Will this $2 AI stock double overnight?

It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!

Click here to learn more >>>

About iTeos Therapeutics Stock (NASDAQ:ITOS)

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

ITOS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ITOS Stock News Headlines

April 16, 2024 | investing.com

Iteos Therapeutics Inc (ITOS)

April 7, 2024 | globenewswire.com

iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

March 22, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: iTeos Therapeutics (ITOS), Rani Therapeutics Holdings (RANI) and Vor Biopharma (VOR)

March 11, 2024 | finance.yahoo.com

ITOS Oct 2024 17.000 call

March 11, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: iTeos Therapeutics (ITOS), Viracta Therapeutics (VIRX)

March 10, 2024 | finance.yahoo.com

ITOS Oct 2024 12.000 call

March 10, 2024 | finance.yahoo.com

ITOS Mar 2024 4.000 put

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 6, 2024 | finanznachrichten.de

iTeos Therapeutics Inc.: iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

March 6, 2024 | finance.yahoo.com

ITOS Mar 2024 11.000 call

March 6, 2024 | globenewswire.com

iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors

March 6, 2024 | globenewswire.com

iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

March 5, 2024 | globenewswire.com

iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024

March 1, 2024 | globenewswire.com

iTeos to Participate in Upcoming Investor Conferences

January 3, 2024 | finance.yahoo.com

iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 13, 2023 | finance.yahoo.com

Wall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 243.43%: Here's is How to Trade

November 29, 2023 | fool.com

iTeos Therapeutics (NASDAQ: ITOS)

November 27, 2023 | finance.yahoo.com

Does iTeos Therapeutics, Inc. (ITOS) Have the Potential to Rally 283.59% as Wall Street Analysts Expect?

November 21, 2023 | finance.yahoo.com

iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference

November 14, 2023 | markets.businessinsider.com

iTeos Therapeutics’ Anticipated Growth and Clinical Updates Drive Buy Rating: An Analyst’s Perspective

November 13, 2023 | finance.yahoo.com

Here's Why iTeos Therapeutics, Inc. (ITOS) Could be Great Choice for a Bottom Fisher

November 10, 2023 | finance.yahoo.com

Wall Street Analysts Predict a 304.26% Upside in iTeos Therapeutics, Inc. (ITOS): Here's What You Should Know

November 10, 2023 | finance.yahoo.com

Wall Street Analysts Predict a 304.26% Upside in iTeos Therapeutics, Inc. (ITOS): Here's What You Should Know

November 9, 2023 | markets.businessinsider.com

Positive Financial Results and Promising Cancer Treatment Programs Underpin Buy Rating for iTeos Therapeutics

November 7, 2023 | finance.yahoo.com

iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates

October 31, 2023 | finance.yahoo.com

Viridian Therapeutics, Inc. (VRDN) Stock Jumps 5.2%: Will It Continue to Soar?

See More Headlines

Receive ITOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/06/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:ITOS
CUSIP: N/A
CIK: 1808865
Web: www.iteostherapeutics.com
Phone: 339-217-0161
Fax: N/A
Employees: 157
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $30.33
High Stock Price Target: $44.00
Low Stock Price Target: $18.00
Potential Upside/Downside: +193.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.15)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-112,640,000.00
Net Margins: N/A
Pretax Margin: -865.66%
Return on Equity: -18.40%
Return on Assets: -16.22%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 13.76
Quick Ratio: 13.76

Sales & Book Value

Annual Sales: $12.60 million
Price / Sales: 29.38
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $16.08 per share
Price / Book: 0.64

Miscellaneous

Outstanding Shares: 35,840,000
Free Float: 32,187,000
Market Cap: $370.23 million
Optionable: Optionable
Beta: 1.19

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Dr. Michel Detheux Ph.D. (Age 57)
President, CEO & Director
Comp: $922.38k
Mr. Matthew A. Call M.B.A. (Age 51)
Chief Operating Officer
Comp: $638.55k
Mr. Matthew Gall (Age 46)
Chief Financial Officer
Comp: $628.45k
Dr. Yvonne McGrath Ph.D. (Age 50)
Chief Scientific Officer
Dr. Joyson Joseph Karakunnel FACP (Age 53)
M.D., M.Sc., Interim Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ITOS Stock Analysis - Frequently Asked Questions

Should I buy or sell iTeos Therapeutics stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for iTeos Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ITOS shares.
View ITOS analyst ratings or view top-rated stocks.
What is iTeos Therapeutics' stock price target for 2024?: 3 brokerages have issued twelve-month price objectives for iTeos Therapeutics' stock. Their ITOS share price targets range from $18.00 to $44.00. On average, they predict the company's stock price to reach $30.33 in the next twelve months. This suggests a possible upside of 200.9% from the stock's current price.
View analysts price targets for ITOS or view top-rated stocks among Wall Street analysts.
How have ITOS shares performed in 2024?: iTeos Therapeutics' stock was trading at $10.95 at the start of the year. Since then, ITOS stock has decreased by 7.9% and is now trading at $10.08.
View the best growth stocks for 2024 here.
When is iTeos Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our ITOS earnings forecast.
How were iTeos Therapeutics' earnings last quarter?: iTeos Therapeutics, Inc. (NASDAQ:ITOS) posted its quarterly earnings data on Wednesday, March, 6th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($1.03) by $0.18.
What ETFs hold iTeos Therapeutics' stock?: ETFs with the largest weight of iTeos Therapeutics (NASDAQ:ITOS) stock in their portfolio include Loncar China Biopharma ETF (CHNA) and Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of iTeos Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other iTeos Therapeutics investors own include Advanced Micro Devices (AMD), GW Pharmaceuticals (GWPH), Trevena (TRVN), Blink Charging (BLNK), Chegg (CHGG), Centene (CNC), Datadog (DDOG), Global Blood Therapeutics (GBT) and Genocea Biosciences (GNCA).
When did iTeos Therapeutics IPO?: iTeos Therapeutics (ITOS) raised $151 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are iTeos Therapeutics' major shareholders?: iTeos Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.08%) and Allspring Global Investments Holdings LLC (0.03%). Insiders that own company stock include Aaron I Davis, Ansbert Gadicke, Bioventures 2014 LP Mpm, Bioventures 2018 LP Mpm, Boxer Capital, Llc, David Hallal, Detlev Biniszkiewicz, Joanne Jenkins Lager, Les B Korsh, Matthew Gall, Michel Detheux and Yvonne Mcgrath.
View institutional ownership trends.
How do I buy shares of iTeos Therapeutics?: Shares of ITOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ITOS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial